Advances in CAR T Cell Tx for MM

CME

Independent Conference Highlights From IMS 2024: Recent Advances in CAR T-Cell Therapies for Multiple Myeloma

Physicians: Maximum of 0.25 AMA PRA Category 1 Credit

Released: November 01, 2024

Expiration: April 30, 2025

Nikhil Munshi
Nikhil Munshi, MD

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Which of the following outcomes were reported from the phase III CARTITUDE-4 study comparing cilta-cel vs standard-of-care (SOC) pomalidomide/bortezomib/dexamethasone or daratumumab/pomalidomide/dexamethasone?